| Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia ES Rosenberg, JM Billingsley, AM Caliendo, SL Boswell, PE Sax, ... Science 278 (5342), 1447-1450, 1997 | 2383 | 1997 |
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation International HIV Controllers Study Science 330 (6010), 1551-1557, 2010 | 1109 | 2010 |
| Transmission of SARS-CoV-2: a review of viral, host, and environmental factors EA Meyerowitz, A Richterman, RT Gandhi, PE Sax Annals of internal medicine 174 (1), 69-79, 2021 | 968 | 2021 |
| Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy C Hadigan, JB Meigs, C Corcoran, P Rietschel, S Piecuch, N Basgoz, ... Clinical Infectious Diseases 32 (1), 130-139, 2001 | 882 | 2001 |
| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel HF Günthard, MS Saag, CA Benson, C Del Rio, JJ Eron, JE Gallant, ... Jama 316 (2), 191-210, 2016 | 839 | 2016 |
| The survival benefits of AIDS treatment in the United States RP Walensky, AD Paltiel, E Losina, LM Mercincavage, BR Schackman, ... The Journal of infectious diseases 194 (1), 11-19, 2006 | 742 | 2006 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two … PE Sax, D Wohl, MT Yin, F Post, E DeJesus, M Saag, A Pozniak, ... The Lancet 385 (9987), 2606-2615, 2015 | 736* | 2015 |
| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel MS Saag, CA Benson, RT Gandhi, JF Hoy, RJ Landovitz, MJ Mugavero, ... Jama 320 (4), 379-396, 2018 | 712 | 2018 |
| The lifetime cost of current human immunodeficiency virus care in the United States BR Schackman, KA Gebo, RP Walensky, E Losina, T Muccio, PE Sax, ... Medical care 44 (11), 990-997, 2006 | 602 | 2006 |
| Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz … GA McComsey, D Kitch, ES Daar, C Tierney, NC Jahed, P Tebas, L Myers, ... Journal of Infectious Diseases 203 (12), 1791-1801, 2011 | 591 | 2011 |
| Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials PE Sax, KM Erlandson, JE Lake, GA Mccomsey, C Orkin, S Esser, ... Clinical Infectious Diseases 71 (6), 1379-1389, 2020 | 579 | 2020 |
| Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1 S Naggie, C Cooper, M Saag, K Workowski, P Ruane, WJ Towner, ... New England Journal of Medicine 373 (8), 705-713, 2015 | 568 | 2015 |
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a … PE Sax, E DeJesus, A Mills, A Zolopa, C Cohen, D Wohl, JE Gallant, ... The Lancet 379 (9835), 2439-2448, 2012 | 528 | 2012 |
| Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection M Altfeld, ES Rosenberg, R Shankarappa, JS Mukherjee, FM Hecht, ... The Journal of experimental medicine 193 (2), 169-180, 2001 | 518 | 2001 |
| Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial C Hadigan, C Corcoran, N Basgoz, B Davis, P Sax, S Grinspoon Jama 284 (4), 472-477, 2000 | 467 | 2000 |
| Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials JB Nachega, JJ Parienti, OA Uthman, R Gross, DW Dowdy, PE Sax, ... Clinical infectious diseases 58 (9), 1297-1307, 2014 | 460 | 2014 |
| Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy JS Currier, JD Lundgren, A Carr, D Klein, CA Sabin, PE Sax, JT Schouten, ... Circulation 118 (2), e29-e35, 2008 | 449 | 2008 |
| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA Panel MS Saag, RT Gandhi, JF Hoy, RJ Landovitz, MA Thompson, PE Sax, ... Jama 324 (16), 1651-1669, 2020 | 447 | 2020 |
| Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy PE Sax, C Tierney, AC Collier, MA Fischl, K Mollan, L Peeples, C Godfrey, ... New England Journal of Medicine 361 (23), 2230-2240, 2009 | 429 | 2009 |
| Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ... The Journal of infectious diseases 210 (3), 354-362, 2014 | 415 | 2014 |
